CoChat
Sign Up
Cited by 513Diabetes Management and EducationDiabetes Management and ResearchDiabetes Treatment and Management

The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan

Handelsman, Yehuda, Mechanick, Jeffrey I., Blonde, Lawrence, Grunberger, George, Bloomgarden, Zachary T., Bray, George A., Dagogo-Jack, Samuel, Davidson, Jaime A., Einhorn, Daniel, Ganda, Om, Garber, Alan J., Hirsch, Irl B., Horton, Edward S., Ismail-Beigi, Faramarz, Jellinger, Paul S., Jones, Kenneth L., Jovanovič, Lois, Lebovitz, Harold, Levy, Philip, Moghissi, Etie S., Orzeck, Eric A., Vinik, Aaron I., Wyne, Kathleen L., Garber, Alan J., Hurley, Daniel L., Zangeneh, Farhad·2011·Endocrine Practice
DOI 10.4158/ep.17.s2.1
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.4158/ep.17.s2.1

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 274

  1. Mechanick, 2010, American Association of Clinical Endocrinologists Protocol for Standardized Production of Clinical Practice Guidelines--2010 update, Endocr Pract, 16, 270, 10.4158/EP.16.2.270 · DOI
  2. Garber, 2008, Diagnosis and management of prediabetes in the continuum of hyperglycemia: When do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists, Endocr Pract, 14, 933, 10.4158/EP.14.7.933 · DOI
  3. Rodbard, 2009, Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control [Erratum in Endocr Pract. 2009;15:768-770], Endocr Pract, 15, 540, 10.4158/EP.15.6.540 · DOI · Paper page
  4. Moghissi, 2009, American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control, Endocr Pract, 15, 353, 10.4158/EP09102.RA · DOI
  5. Chobanian, 2003, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report [Erratum in: JAMA. 2003;290:197], JAMA, 289, 2560, 10.1001/jama.289.19.2560 · DOI · Paper page
  6. Younis, 2010, Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A meta-analysis, Expert Opin Pharmacother, 11, 1459, 10.1517/14656561003792538 · DOI
  7. Baigent, 2009, Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials, Lancet, 373, 1849, 10.1016/S0140-6736(09)60503-1 · DOI · Paper page
  8. Zhang, 2010, Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis, Diabetes Res Clin Pract, 87, 211, 10.1016/j.diabres.2009.09.029 · DOI · Paper page
  9. Ong, 2010, Aspirin is associated with reduced cardiovascular and all-cause mortality in type 2 diabetes in a primary prevention setting: The Fremantle Diabetes study, Diabetes Care, 33, 317, 10.2337/dc09-1701 · DOI
  10. Hanas, 2009, ISPAD clinical practice consensus guidelines 2009 compendium. Introduction, Pediatr Diabetes, 10, 1, 10.1111/j.1399-5448.2009.00577.x · DOI
  11. Dagogo-Jack, 2010, Pitfalls in the use of HbA1(c) as a diagnostic test: The ethnic conundrum, Nat Rev Endocrinol., 6, 589, 10.1038/nrendo.2010.126 · DOI · Paper page
  12. Sacks, 2011, A1C versus glucose testing: A comparison, Diabetes care, 34, 518, 10.2337/dc10-1546 · DOI · Paper page
  13. UK Prospective Diabetes Study (UKPDS), 1991, VIII. Study design, progress and performance, Diabetologia, 34, 877
  14. Torgerson, 2004, XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients [Erratum in Diabetes Care. 2004;27:856], Diabetes Care., 27, 155, 10.2337/diacare.27.1.155 · DOI · Paper page
  15. Chiasson, 2002, Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial, Lancet, 359, 2072, 10.1016/S0140-6736(02)08905-5 · DOI · Paper page
  16. Chiasson, 2003, Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial, JAMA, 290, 486, 10.1001/jama.290.4.486 · DOI · Paper page
  17. Chiasson, 2004, Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: Facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data, Diabetologia, 47, 969, 10.1007/s00125-004-1409-4 · DOI
  18. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, 2006, Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial [Erratum in: Lancet. 2006;368:1770], Lancet, 368, 1096, 10.1016/S0140-6736(06)69420-8 · DOI · Paper page
  19. Richelsen, 2007, Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: A 3-year randomized, placebo-controlled study, Diabetes Care, 30, 27, 10.2337/dc06-0210 · DOI
  20. Norris, 2004, Efficacy of phar-macotherapy for weight loss in adults with type 2 diabetes mellitus: A meta-analysis, Arch Intern Med, 164, 1395, 10.1001/archinte.164.13.1395 · DOI
  21. Hutton, 2004, Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: A systematic review of randomized clinical trials, Am J Clin Nutr, 80, 1461, 10.1093/ajcn/80.6.1461 · DOI
  22. Li, 2005, Meta-analysis: Pharmacologic treatment of obesity, Ann Intern Med, 142, 532, 10.7326/0003-4819-142-7-200504050-00012 · DOI · Paper page
  23. Arterburn, 2009, Predictors of long-term mortality after bariatric surgery performed in Veterans Affairs medical centers, Arch Surg, 144, 914, 10.1001/archsurg.2009.134 · DOI
  24. Cremieux, 2008, A study on the economic impact of bariatric surgery, Am J Manag Care, 14, 589
  25. Sampalis, 2004, The impact of weight reduction surgery on health-care costs in morbidly obese patients, Obes Surg, 14, 939, 10.1381/0960892041719662 · DOI
  26. Salem, 2005, Are bariatric surgical outcomes worth their cost? A systematic review, J Am Coll Surg., 200, 270, 10.1016/j.jamcollsurg.2004.09.045 · DOI
  27. Tice, 2008, Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures, Am J Med, 121, 885, 10.1016/j.amjmed.2008.05.036 · DOI
  28. Long, 1994, Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study, Diabetes Care., 17, 372, 10.2337/diacare.17.5.372 · DOI
  29. Torquati, 2005, Is Roux-en-Y gastric bypass surgery the most effective treatment for type 2 diabetes mellitus in morbidly obese patients?, J Gastrointest Surg., 9, 1112, 10.1016/j.gassur.2005.07.016 · DOI
  30. Mari, 2006, Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: Role of insulin sensitivity and beta cell function, Diabetologia, 49, 2136, 10.1007/s00125-006-0337-x · DOI
  31. Schauer, 2003, The learning curve for laparoscopic Roux-en-Y gastric bypass is 100 cases, Surg Endosc, 17, 212, 10.1007/s00464-002-8857-z · DOI
  32. Torgerson, 2001, The Swedish Obese Subjects (SOS) study--rationale and results, Int J Obes Relat Metab Disord., 25, S2, 10.1038/sj.ijo.0801687 · DOI
  33. Dixon, 2008, Adjustable gastric banding and conventional therapy for type 2 diabetes: A randomized controlled trial, JAMA, 299, 316, 10.1001/jama.299.3.316 · DOI · Paper page
  34. Burguera, 2007, Critical assessment of the current guidelines for the management and treatment of morbidly obese patients, J Endocrinol Invest., 30, 844, 10.1007/BF03349226 · DOI
  35. 1998, BMJ, 317, 703, 10.1136/bmj.317.7160.703 · DOI · Paper page
  36. Adler, 2003, Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64), Kidney Int, 63, 225, 10.1046/j.1523-1755.2003.00712.x · DOI
  37. Ohkubo, 1995, Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study, Diabetes Res Clin Pract., 28, 103, 10.1016/0168-8227(95)01064-K · DOI · Paper page
  38. Hayashino, 2007, Normal fasting plasma glucose levels and type 2 diabetes: The high-risk and population strategy for occupational health promotion (HIPOP-OHP) [corrected] study [Erratum in: Acta Diabetol. 2007;44:241], Acta Diabetol., 44, 164, 10.1007/s00592-007-0258-2 · DOI
  39. Khaw, 2004, Association of hemoglobin A1c with cardiovascular disease and mortality in adults: The European prospective investigation into cancer in Norfolk, Ann Intern Med, 141, 413, 10.7326/0003-4819-141-6-200409210-00006 · DOI · Paper page
  40. 1993, N Engl J Med, 329, 977, 10.1056/NEJM199309303291401 · DOI · Paper page
  41. 1996, Diabetes, 45, 1289, 10.2337/diab.45.10.1289 · DOI
  42. 1999, Lancet, 354, 617, 10.1016/S0140-6736(98)12131-1 · DOI · Paper page
  43. Griesdale, 2009, Intensive insulin therapy and mortality among critically ill patients: A meta-analysis including NICE-SUGAR study data, CMAJ, 180, 821, 10.1503/cmaj.090206 · DOI · Paper page
  44. Qaseem, 2011, Use of Intensive Insulin Therapy for the Management of Glycemic Control in Hospitalized Patients: A Clinical Practice Guideline From the American College of Physicians, Ann Intern Med, 154, 260, 10.7326/0003-4819-154-4-201102150-00007 · DOI
  45. Kansagara, 2011, Intensive insulin therapy in hospitalized patients: A systematic review, Ann Intern Med., 154, 268, 10.7326/0003-4819-154-4-201102150-00008 · DOI
  46. van den Berghe, 2001, Intensive insulin therapy in the critically ill patients, N Engl J Med, 345, 1359, 10.1056/NEJMoa011300 · DOI · Paper page
  47. Krinsley, 2008, Glycemic variability: A strong independent predictor of mortality in critically ill patients, Crit Care Med, 36, 3008, 10.1097/CCM.0b013e31818b38d2 · DOI · Paper page
  48. Ali, 2008, Glucose variability and mortality in patients with sepsis, Crit Care Med, 36, 2316, 10.1097/CCM.0b013e3181810378 · DOI
  49. Grundy, 2004, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, J Am Coll Cardiol., 44, 720, 10.1016/j.jacc.2004.07.001 · DOI · Paper page
  50. Corsino, 2009, Patient characteristics associated with receipt of lifestyle behavior advice, N C Med J., 70, 391
  51. Craig, 2009, Position of the American Dietetic Association: Vegetarian diets, J Am Diet Assoc, 109, 1266, 10.1016/j.jada.2009.05.027 · DOI
  52. Jones, 2008, Grain foods and health: A primer for clinicians, Phys Sportsmed., 36, 18, 10.3810/psm.2008.12.8 · DOI
  53. Pawlak, 2009, Benefits, barriers, self-efficacy and knowledge regarding healthy foods; perception of African Americans living in eastern North Carolina, Nutr Res Pract, 3, 56, 10.4162/nrp.2009.3.1.56 · DOI
  54. Birlouez-Aragon, 2010, A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases, Am J Clin Nutr., 91, 1220, 10.3945/ajcn.2009.28737 · DOI
  55. Vuksan, 2009, Fiber facts: Benefits and recommendations for individuals with type 2 diabetes, Curr Diab Rep., 9, 405, 10.1007/s11892-009-0062-1 · DOI
  56. Trinidad, 2010, The potential health benefits of legumes as a good source of dietary fibre, Br J Nutr., 103, 569, 10.1017/S0007114509992157 · DOI
  57. Hare-Bruun, 2008, Should glycemic index and glycemic load be considered in dietary recommendations?, Nutr Rev., 66, 569, 10.1111/j.1753-4887.2008.00108.x · DOI
  58. Palou, 2009, On the role and fate of sugars in human nutrition and health, Introduction. Obes Rev., 10, 1
  59. Minihane, 2007, Impact of oil used by the frying industry on population fat intake, Crit Rev Food Sci Nutr., 47, 287, 10.1080/10408390600737821 · DOI
  60. Vang, 2008, Meats, processed meats, obesity, weight gain and occurrence of diabetes among adults: Findings from Adventist Health Studies [Erratum in: Ann Nutr Metab. 201;56:232], Ann Nutr Metab., 52, 96, 10.1159/000121365 · DOI
  61. Mechanick, 2003, American Association of Clinical Endocrinologists medical guidelines for the clinical use of dietary supplements and nutraceuticals [Erratum in: Endocr Pract. 2008;14:802-803], Endocr Pract, 9, 417, 10.4158/EP.9.5.417 · DOI · Paper page
  62. Micha, 2010, Saturated fat and cardiometabolic risk factors, coronary heart disease, stroke, and diabetes: A fresh look at the evidence, Lipids., 45, 893, 10.1007/s11745-010-3393-4 · DOI · Paper page
  63. Booker, 2008, Trans fatty acids and cardiovascular health: Translation of the evidence base, Nutr Metab Cardiovasc Dis., 18, 448, 10.1016/j.numecd.2008.02.005 · DOI
  64. 2011, Diabetes Care, 34, S3
  65. Colberg, 2010, Exercise and type 2 diabetes: The American College of Sports Medicine and the American Diabetes Association: Joint position statement executive summary, Diabetes Care, 33, 2692, 10.2337/dc10-1548 · DOI
  66. Praet, 2006, Influence of acute exercise on hyperglycemia in insulin-treated type 2 diabetes, Med Sci Sports Exerc, 38, 2037, 10.1249/01.mss.0000235352.09061.1d · DOI · Paper page
  67. De Feyter, 2007, Exercise training improves glycemic control in long-standing insulin-treated type 2 diabetic patients, Diabetes Care., 30, 2511, 10.2337/dc07-0183 · DOI · Paper page
  68. Church, 2010, Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: A randomized controlled trial [Erratum in: JAMA. 2011;305:892], JAMA., 304, 2253, 10.1001/jama.2010.1710 · DOI · Paper page
  69. Balducci, 2007, Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: A meta-analysis: Response to Snowling and Hopkins, Diabetes Care., 30, 10.2337/dc06-2495 · DOI
  70. Phung, 2010, Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes, JAMA., 303, 1410, 10.1001/jama.2010.405 · DOI · Paper page
  71. Parchman, 2007, Glucose control, self-care behaviors, and the presence of the chronic care model in primary care clinics, Diabetes Care., 30, 2849, 10.2337/dc06-2516 · DOI
  72. 1998, Lancet, 352, 854, 10.1016/S0140-6736(98)07037-8 · DOI · Paper page
  73. Belsey, 2008, Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: A meta-analysis, Diabetes Obes Metab, 10, 1, 10.1111/j.1463-1326.2008.00884.x · DOI
  74. Bolen, 2007, Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus [Erratum in: Ann Intern Med. 2007;147:887], Ann Intern Med., 147, 386, 10.7326/0003-4819-147-6-200709180-00178 · DOI
  75. Bloomgarden, 2008, What role will ‘gliptins’ play in glycemic control, Cleve Clin J Med, 75, 305, 10.3949/ccjm.75.4.305 · DOI
  76. Williams-Herman, 2010, Safety and tolerability of sitagliptin in clinical studies: A pooled analysis of data from 10,246 patients with type 2 diabetes, BMC Endocr Disord., 10, 7, 10.1186/1472-6823-10-7 · DOI
  77. Stein, 2009, Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status, Adv Ther., 26, 893, 10.1007/s12325-009-0072-z · DOI
  78. Gerstein, 2010, Circulation, 121, 1176, 10.1161/CIRCULATIONAHA.109.881003 · DOI
  79. Riche, 2007, Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: A meta-analysis, Diabetes Care., 30, 384, 10.2337/dc06-1854 · DOI
  80. Abbatecola, 2010, Adiposity predicts cognitive decline in older persons with diabetes: A 2-year follow-up, PLoS One, 5, e10333, 10.1371/journal.pone.0010333 · DOI
  81. Woodcock, 2010, Regulatory action on rosiglitazone by the U.S. Food and Drug Administration, N Engl J Med., 363, 1489, 10.1056/NEJMp1010788 · DOI
  82. Pijl, 2000, Bromocriptine: A novel approach to the treatment of type 2 diabetes, Diabetes Care., 23, 1154, 10.2337/diacare.23.8.1154 · DOI
  83. Nauck, 1997, Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes, Exp Clin Endocrinol Diabetes, 105, 187, 10.1055/s-0029-1211750 · DOI
  84. Drucker, 2006, The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes, Lancet., 368, 1696, 10.1016/S0140-6736(06)69705-5 · DOI · Paper page
  85. Amori, 2007, Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis, JAMA., 298, 194, 10.1001/jama.298.2.194 · DOI · Paper page
  86. Nauck, 1997, Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans, Am J Physiol., 273, E981
  87. Pi-Sunyer, 2008, The effects of pharmacologic agents for type 2 diabetes mellitus on body weight, Postgrad Med., 120, 5, 10.3810/pgm.2008.07.1785 · DOI
  88. Arnolds, 2010, Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: A proof-of-concept study, Diabetes care., 33, 1509, 10.2337/dc09-2191 · DOI
  89. Riddle, 2006, Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin, Diabetes Metab Res Rev., 22, 483, 10.1002/dmrr.646 · DOI
  90. DeFronzo, 2005, Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes, Diabetes Care., 28, 1092, 10.2337/diacare.28.5.1092 · DOI · Paper page
  91. Zinman, 2007, The effect of adding exenatide to a thiazolidinedione in sub-optimally controlled type 2 diabetes: A randomized trial [Erratum in: Ann Intern Med. 2007;146:896], Ann Intern Med., 146, 477, 10.7326/0003-4819-146-7-200704030-00003 · DOI
  92. Larsen, 2008, Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats, Diabetes Obes Metab., 10, 301, 10.1111/j.1463-1326.2008.00865.x · DOI
  93. Zinman, 2009, Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD) [Erratum in: Diabetes Care. 2010;33:692], Diabetes Care., 32, 1224, 10.2337/dc08-2124 · DOI · Paper page
  94. Nauck, 2009, Adding liraglutide to oral antidiabetic drug monotherapy: Efficacy and weight benefits, Postgrad Med., 121, 5, 10.3810/pgm.2009.05.1997 · DOI
  95. Marre, 2009, Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU), Diabet Med, 26, 268, 10.1111/j.1464-5491.2009.02666.x · DOI
  96. Russell-Jones, 2009, Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial, Diabetologia, 52, 2046, 10.1007/s00125-009-1472-y · DOI · Paper page
  97. Bergenstal, 2009, Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea, Curr Med Res Opin, 25, 65, 10.1185/03007990802597951 · DOI
  98. Blevins, 2010, Exenatide is non-inferior to insulin in reducing A1C: An integrated analysis of 1423 patients with type 2 diabetes, Postgrad Med., 122, 118, 10.3810/pgm.2010.05.2149 · DOI
  99. Parks, 2010, Weighing risks and benefits of liraglutide--the FDA’s review of a new antidiabetic therapy, N Engl J Med., 362, 774, 10.1056/NEJMp1001578 · DOI
  100. Buse, 2011, Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: A randomized, controlled trial, Ann Intern Med., 154, 103, 10.7326/0003-4819-154-2-201101180-00300 · DOI · Paper page
  101. Buse, 2009, Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6), Lancet., 374, 39, 10.1016/S0140-6736(09)60659-0 · DOI · Paper page
  102. Pratley, 2010, Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trial [Erratum in: Lancet. 2010;376:234], Lancet., 375, 1447, 10.1016/S0140-6736(10)60307-8 · DOI
  103. Bergenstal, 2010, Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial, Lancet, 376, 431, 10.1016/S0140-6736(10)60590-9 · DOI
  104. Garber, 2010, Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for two years as monotherapy compared with glimepiride in patients with type 2 diabetes, Diabetes Obes Metab., 13, 348, 10.1111/j.1463-1326.2010.01356.x · DOI
  105. Riddle, 2003, The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients, Diabetes Care, 26, 3080, 10.2337/diacare.26.11.3080 · DOI
  106. Monami, 2008, Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: A meta-analysis, Diabetes Res Clin Pract., 81, 184, 10.1016/j.diabres.2008.04.007 · DOI · Paper page
  107. Mann, 2004, Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus, Nutr Metab Cardiovasc Dis, 14, 373, 10.1016/S0939-4753(04)80028-0 · DOI
  108. Monami, 2009, Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis, Diabetes Obes Metab., 11, 372, 10.1111/j.1463-1326.2008.00976.x · DOI
  109. Devries, 2007, Refining basal insulin therapy: What have we learned in the age of analogues?, Diabetes Metab Res Rev., 23, 441, 10.1002/dmrr.762 · DOI
  110. Meneghini, 2007, The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes-results of the randomized, controlled PREDICTIVE 303 study, Diabetes Obes Metab., 9, 902, 10.1111/j.1463-1326.2007.00804.x · DOI
  111. Mannucci, 2009, Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: A meta-analysis, Diabetes Obes Metab., 11, 53, 10.1111/j.1463-1326.2008.00934.x · DOI · Paper page
  112. Singh, 2009, Efficacy and safety of insulin analogues for the management of diabetes mellitus: A meta-analysis, CMAJ., 180, 385, 10.1503/cmaj.081041 · DOI
  113. Edelman, 2006, A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes, Diabetes Care., 29, 2189, 10.2337/dc06-0042 · DOI · Paper page
  114. Ratner, 2004, Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial, Diabet Med., 21, 1204, 10.1111/j.1464-5491.2004.01319.x · DOI · Paper page
  115. Fritsche, 2010, Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study [Erratum in Diabetes Obes Metab. 2010;12:1022], Diabetes Obes Metab., 12, 115, 10.1111/j.1463-1326.2009.01165.x · DOI
  116. Misso, 2010, Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus, Cochrane Database Syst Rev, CD005103
  117. Monami, 2009, Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: A meta-analysis, Exp Clin Endocrinol Diabetes., 117, 220, 10.1055/s-0028-1119405 · DOI
  118. Bruttomesso, 2009, Continuous subcutaneous insulin infusion (CSII) 30 years later: Still the best option for insulin therapy, Diabetes Metab Res Rev., 25, 99, 10.1002/dmrr.931 · DOI
  119. American Diabetes Association, 2004, Continuous subcutaneous insulin infusion, Diabetes Care, 27, S110, 10.2337/diacare.27.2007.S110 · DOI
  120. Eugster, 2006, Position statement: Continuous subcutaneous insulin infusion in very young children with type 1 diabetes, Pediatrics., 118, e1244, 10.1542/peds.2006-0662 · DOI
  121. Phillip, 2007, Diabetes Care, 30, 1653, 10.2337/dc07-9922 · DOI
  122. Grunberger, 2010, Statement by the American Association of Clinical Endocrinologists consensus panel on insulin pump management, Endocr Pract, 16, 762
  123. Weissberg-Benchell, 2003, Insulin pump therapy: A meta-analysis, Diabetes Care., 26, 1079, 10.2337/diacare.26.4.1079 · DOI
  124. Jeitler, 2008, Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: Systematic review and meta-analysis, Diabetologia., 51, 941, 10.1007/s00125-008-0974-3 · DOI · Paper page
  125. Fatourechi, 2009, Clinical review: Hypoglycemia with intensive insulin therapy: A systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections, J Clin Endocrinol Metab., 94, 729, 10.1210/jc.2008-1415 · DOI
  126. Pickup, 2008, Severe hypoglycaemia and glycaemic control in type 1 diabetes: Meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion, Diabet Med., 25, 765, 10.1111/j.1464-5491.2008.02486.x · DOI
  127. Monami, 2009, Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: A meta-analysis, Acta Diabetol., 47, 77
  128. St Charles, 2009, A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: A third-party US payer perspective, Value Health., 12, 674, 10.1111/j.1524-4733.2008.00478.x · DOI
  129. St Charles, 2009, Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada, Clin Ther., 31, 657, 10.1016/j.clinthera.2009.03.013 · DOI
  130. Cummins, 2010, Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: Systematic review and economic evaluation, Health Technol Assess, 14, 1, 10.3310/hta14110 · DOI
  131. Cohen, 2008, Macrosomia in well controlled CSII treated type I diabetic pregnancy, Gynecol Endocrinol., 24, 611, 10.1080/09513590802531062 · DOI
  132. Roze, 2005, Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK, Diabet Med., 22, 1239, 10.1111/j.1464-5491.2005.01576.x · DOI
  133. Vaxillaire, 2008, Monogenic diabetes in the young, pharmacogenetics and relevance to multifactorial forms of type 2 diabetes, Endocr Rev., 29, 254, 10.1210/er.2007-0024 · DOI
  134. Fajans, 2001, Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young, N Engl J Med., 345, 971, 10.1056/NEJMra002168 · DOI · Paper page
  135. Herman, 1994, Abnormal insulin secretion, not insulin resistance, is the genetic or primary defect of MODY in the RW pedigree, Diabetes., 43, 40, 10.2337/diab.43.1.40 · DOI
  136. Holmkvist, 2008, Common variants in maturity-onset diabetes of the young genes and future risk of type 2 diabetes, Diabetes., 57, 1738, 10.2337/db06-1464 · DOI
  137. Nyunt, 2009, Investigating maturity onset diabetes of the young, Clin Biochem Rev., 30, 67
  138. Weng, 2002, Screening for MODY mutations, GAD antibodies, and type 1 diabetes-associated HLA genotypes in women with gestational diabetes mellitus, Diabetes Care., 25, 68, 10.2337/diacare.25.1.68 · DOI
  139. Litton, 2002, Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus, J Pediatr., 141, 490, 10.1067/mpd.2002.127500 · DOI
  140. Johnson, 1992, A longitudinal analysis of adherence and health status in childhood diabetes, J Pediatr Psychol., 17, 537, 10.1093/jpepsy/17.5.537 · DOI
  141. Pettitt, 1983, Excessive obesity in offspring of Pima Indian women with diabetes during pregnancy, N Engl J Med., 308, 242, 10.1056/NEJM198302033080502 · DOI · Paper page
  142. Knowler, 1990, Diabetes mellitus in the Pima Indians: Incidence, risk factors and pathogenesis, Diabetes Metab Rev., 6, 1, 10.1002/dmr.5610060101 · DOI · Paper page
  143. Cypryk, 2004, Pregnancy complications and perinatal outcome in diabetic women treated with Humalog (insulin lispro) or regular human insulin during pregnancy, Med Sci Monit., 10, PI29
  144. Lapolla, 2008, Outcome of pregnancy in type 1 diabetic patients treated with insulin lispro or regular insulin: An Italian experience, Acta Diabetol, 45, 61, 10.1007/s00592-008-0024-0 · DOI · Paper page
  145. Masson, 2003, Pregnancy outcome in type 1 diabetes mellitus treated with insulin lispro (Humalog), Diabet Med., 20, 46, 10.1046/j.1464-5491.2003.00840.x · DOI
  146. Sciacca, 2010, Use of insulin detemir during pregnancy, Nutr Metab Cardiovasc Dis., 20, e15, 10.1016/j.numecd.2009.12.010 · DOI · Paper page
  147. Lapolla, 2009, Use of insulin detemir in pregnancy: A report on 10 Type 1 diabetic women, Diabetic Med., 26, 1181, 10.1111/j.1464-5491.2009.02852.x · DOI · Paper page
  148. American Diabetes Association, 2010, Standards of medical care in diabetes – 2010, Diabetes Care., 33, S11, 10.2337/dc10-S011 · DOI · Paper page
  149. Hales, 1991, Fetal and infant growth and impaired glucose tolerance at age 64, BMJ., 303, 1019, 10.1136/bmj.303.6809.1019 · DOI · Paper page
  150. Jiang, 2003, Multiple hospitalizations for patients with diabetes, Diabetes Care., 26, 1421, 10.2337/diacare.26.5.1421 · DOI · Paper page
  151. Clement, 2004, Management of diabetes and hyperglycemia in hospitals, Diabetes Care., 27, 553, 10.2337/diacare.27.2.553 · DOI · Paper page
  152. Hirsch, 2010, Interference of home blood glucose measurements and poor outcomes: A solvable problem requiring broader exposure, Diabetes Technol Ther., 12, 245, 10.1089/dia.2010.0013 · DOI
  153. Davidson, 2007, A cause-and-effect-based mathematical curvilinear model that predicts the effects of self-monitoring of blood glucose frequency on hemoglobin A1c and is suitable for statistical correlations, J Diabetes Sci Technol., 1, 850, 10.1177/193229680700100608 · DOI · Paper page
  154. Davis, 2010, STAR 3 randomized controlled trial to compare sensor-augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects, Diabetes Technol Ther., 12, 249, 10.1089/dia.2009.0145 · DOI · Paper page
  155. Pearce, 2008, Effect of carbohydrate distribution on postprandial glucose peaks with the use of continuous glucose monitoring in type 2 diabetes, Am J Clin Nutr., 87, 638, 10.1093/ajcn/87.3.638 · DOI · Paper page
  156. Whipple, 1938, The surgical therapy of hyperinsulinism, J Int Chir., 3, 237
  157. Fritsche, 2001, Avoidance of hypoglycemia restores hypoglycemia awareness by increasing beta-adrenergic sensitivity in type 1 diabetes, Ann Intern Med., 134, 729, 10.7326/0003-4819-134-9_Part_1-200105010-00009 · DOI · Paper page
  158. Molitch, 1994, ACE inhibitors and diabetic nephropathy, Diabetes Care., 17, 756, 10.2337/diacare.17.7.756 · DOI
  159. Levey, 2003, National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification [Erratum in: Ann Intern Med. 2003;139:605], Ann Intern Med., 139, 137, 10.7326/0003-4819-139-2-200307150-00013 · DOI · Paper page
  160. Kramer, 2005, Screening for kidney disease in adults with diabetes, Diabetes Care., 28, 1813, 10.2337/diacare.28.7.1813 · DOI
  161. Rigalleau, 2005, Estimation of glomerular filtration rate in diabetic subjects: Cockcroft formula or modification of Diet in Renal Disease study equation?, Diabetes Care., 28, 838, 10.2337/diacare.28.4.838 · DOI
  162. 2000, Lancet, 355, 253, 10.1016/S0140-6736(99)12323-7 · DOI · Paper page
  163. 2000, N Engl J Med, 342, 381, 10.1056/NEJM200002103420603 · DOI · Paper page
  164. Halimi, 2009, Optimal nephroprotection: Use, misuse and misconceptions about blockade of the renin-angiotensin system. Lessons from the ONTARGET and other recent trials, Diabetes Metab., 35, 425, 10.1016/j.diabet.2009.05.003 · DOI
  165. Karalliedde, 2006, Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes, J Hum Hypertens., 20, 239, 10.1038/sj.jhh.1001982 · DOI
  166. Ruggenenti, 2004, Preventing microalbuminuria in type 2 diabetes, N Engl J Med., 351, 1941, 10.1056/NEJMoa042167 · DOI
  167. Parving, 2008, Aliskiren combined with losartan in type 2 diabetes and nephropathy, N Engl J Med, 358, 2433, 10.1056/NEJMoa0708379 · DOI
  168. Pedrini, 1996, The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: A meta-analysis, Ann Intern Med., 124, 627, 10.7326/0003-4819-124-7-199604010-00002 · DOI · Paper page
  169. Wolfe, 1999, Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant, N Engl J Med., 341, 1725, 10.1056/NEJM199912023412303 · DOI
  170. Becker, 2000, Simultaneous pancreas-kidney transplantation reduces excess mortality in type 1 diabetic patients with end-stage renal disease, Kidney Int., 57, 2129, 10.1046/j.1523-1755.2000.00064.x · DOI
  171. Nathan, 1993, Long-term complications of diabetes mellitus, N Engl J Med., 328, 1676, 10.1056/NEJM199306103282306 · DOI
  172. Williams, 2004, Epidemiology of diabetic retinopathy and macular oedema: A systematic review, Eye (Lond)., 18, 963, 10.1038/sj.eye.6701476 · DOI · Paper page
  173. Hansen, 2004, Diabetic retinopathy screening using digital non-mydriatic fundus photography and automated image analysis, Acta Ophthalmol Scand., 82, 666, 10.1111/j.1600-0420.2004.00350.x · DOI · Paper page
  174. Ahmed, 2006, The sensitivity and specificity of non-mydriatic digital stereoscopic retinal imaging in detecting diabetic retinopathy, Diabetes Care., 29, 2205, 10.2337/dc06-0295 · DOI · Paper page
  175. Harris, 1992, Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis, Diabetes Care., 15, 815, 10.2337/diacare.15.7.815 · DOI · Paper page
  176. Klein, 1984, The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years, Arch Ophthalmol., 102, 520, 10.1001/archopht.1984.01040030398010 · DOI
  177. Diabetes Control and Complications Trial Research Group, 2000, Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group, Diabetes Care., 23, 1084, 10.2337/diacare.23.8.1084 · DOI · Paper page
  178. Adler, 2000, Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study, BMJ., 321, 412, 10.1136/bmj.321.7258.412 · DOI · Paper page
  179. Ferris, 1999, Treatment of diabetic retinopathy, N Engl J Med., 341, 667, 10.1056/NEJM199908263410907 · DOI
  180. 1985, Arch Ophthalmol, 103, 1796, 10.1001/archopht.1985.01050120030015 · DOI
  181. Thomas, 1997, Classification, differential diagnosis, and staging of diabetic peripheral neuropathy, Diabetes., 46, S54, 10.2337/diab.46.2.S54 · DOI
  182. Boulton, 2005, Diabetic neuropathies: A statement by the American Diabetes Association, Diabetes Care., 28, 956, 10.2337/diacare.28.4.956 · DOI · Paper page
  183. Treede, 2008, Neuropathic pain: Redefnition and a grading system for clinical and research purposes, Neurology., 70, 1630, 10.1212/01.wnl.0000282763.29778.59 · DOI
  184. England, 2005, Distal symmetric polyneuropathy: A definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation, Neurology., 64, 199, 10.1212/01.WNL.0000149522.32823.EA · DOI · Paper page
  185. Dyck, 2006, Modeling chronic glycemic exposure variables as correlates and predictors of microvascular complications of diabetes, Diabetes Care., 29, 2282, 10.2337/dc06-0525 · DOI · Paper page
  186. Dyck, 1999, Risk factors for severity of diabetic polyneuropathy: Intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort, Diabetes Care., 22, 1479, 10.2337/diacare.22.9.1479 · DOI
  187. Archer, 1983, The natural history of acute painful neuropathy in diabetes mellitus, J Neurol Neurosurg Psychiatry., 46, 491, 10.1136/jnnp.46.6.491 · DOI
  188. Singleton, 2001, Painful sensory polyneuropathy associated with impaired glucose tolerance, Muscle Nerve., 24, 1225, 10.1002/mus.1136 · DOI · Paper page
  189. Knuiman, 1986, Prevalence of diabetic complications in relation to risk factors, Diabetes., 35, 1332, 10.2337/diab.35.12.1332 · DOI
  190. Vinik, 2001, Recognizing and treating diabetic autonomic neuropathy, Cleve Clin J Med, 68, 934
  191. Vinik, 2003, Diagnosis and management of diabetic autonomic neuropathy, Compr Ther., 29, 130, 10.1007/s12019-003-0017-4 · DOI
  192. Yu, 1990, Autoimmune mechanisms in peripheral neuropathies, Ann Neurol., 27, S30, 10.1002/ana.410270709 · DOI
  193. Nelson, 1994, Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures. A randomized controlled trial, JAMA., 272, 1909, 10.1001/jama.1994.03520240037038 · DOI
  194. Liu-Ambrose, 2004, Resistance and agility training reduce fall risk in women aged 75 to 85 with low bone mass: A 6-month randomized, controlled trial, J Am Geriatr Soc., 52, 657, 10.1111/j.1532-5415.2004.52200.x · DOI
  195. Cavanagh, 1992, Problems with gait and posture in neuropathic patients with insulin-dependent diabetes mellitus, Diabet Med., 9, 469, 10.1111/j.1464-5491.1992.tb01819.x · DOI
  196. Vinik, 1995, Quantitative measurement of cutaneous perception in diabetic neuropathy, Muscle Nerve., 18, 574, 10.1002/mus.880180603 · DOI
  197. Lauria, 2010, Eur J Neurol., 17, 903, 10.1111/j.1468-1331.2010.03023.x · DOI
  198. Shun, 2004, Skin denervation in type 2 diabetes: Correlations with diabetic duration and functional impairments, Brain., 127, 1593, 10.1093/brain/awh180 · DOI
  199. Loseth, 2008, Early diabetic neuropathy: Thermal thresholds and intraepidermal nerve fibre density in patients with normal nerve conduction studies, J Neurol., 255, 1197, 10.1007/s00415-008-0872-0 · DOI
  200. Quattrini, 2007, Surrogate markers of small fiber damage in human diabetic neuropathy, Diabetes., 56, 2148, 10.2337/db07-0285 · DOI

200 of 274 shown

Cited by

Sorted by citations

See all 513

Metadata

Authors
Handelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G. A., Dagogo-Jack, S., Davidson, J. A., Einhorn, D., Ganda, O., Garber, A. J., Hirsch, I. B., Horton, E. S., Ismail-Beigi, F., Jellinger, P. S., Jones, K. L., Jovanovič, L., Lebovitz, H., Levy, P., Moghissi, E. S., Orzeck, E. A., Vinik, A. I., Wyne, K. L., Garber, A. J., Hurley, D. L., & Zangeneh, F.
Affiliations
American Association of Clinical Endocrinologists (US)
ORCID
Venue
Endocrine Practice
Publisher
Elsevier BV
Published
2011-03
Volume
17
Pages
1-53
ISSN
1530-891X (ISSN-L)
DOI
10.4158/ep.17.s2.1
OpenAlex
W2057002261
Cited by
513
References
0
Citations by year
2026: 3 · 2025: 1 · 2024: 4 · 2023: 9 · 2022: 6 · 2021: 5 · 2020: 6 · 2019: 12 · 2018: 16 · 2017: 24 · 2016: 39 · 2015: 57 · 2014: 104 · 2013: 105 · 2012: 92
FWCI
86.34
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Endocrine Practice (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
diabetes mellitus, comprehensive care plan, diabetes management, care planning
MeSH terms
Diabetes Mellitus, Humans, Randomized Controlled Trials as Topic, Diabetes Complications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review